Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Inflammatory Bowel Diseases

Free Subscription 15.12.2025 1 Aliment Pharmacol Ther 5 Am J Gastroenterol 1 BMC Gastroenterol 1 Clin Res Hepatol Gastroenterol 1 Dig Dis 4 Dig Dis Sci 1 Dis Colon Rectum 1 Gastroenterology 5 Gut 13 Inflamm Bowel Dis 6 J Crohns Colitis 3 PLoS One 1 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. LU C, Verstockt B, Winter MW, Christensen B, et al
   Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance and Expansion.
   Aliment Pharmacol Ther. 2026;63:40-56.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. RUBIN DT, Ananthakrishnan AN, Siegel CA, Barnes EL, et al
   Correction: ACG Clinical Guideline Ulcerative Colitis in Adults.
   Am J Gastroenterol. 2025 Dec 15. doi: 10.14309/ajg.0000000000003828.
   PubMed        
   
   
3. SHUKLA AP
   Continuing Medical Education Questions: June 2025.
   Am J Gastroenterol. 2025;120:1186.
   PubMed         Abstract available
   
   
4. SHUJA A
   Continuing Medical Education Questions: June 2025.
   Am J Gastroenterol. 2025;120:1185.
   PubMed         Abstract available
   
   
5. MESQUITA P, Ponte A, Lage J, Cardoso J, et al
   When Refractory Crohn's Disease Isn't Crohn's: Ileal Endometriosis.
   Am J Gastroenterol. 2025 Dec 12. doi: 10.14309/ajg.0000000000003882.
   PubMed        
   
   
6. RAO BB
   Continuing Medical Education Questions: November 2025.
   Am J Gastroenterol. 2025;120:2484.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

7. KARIMI P, Ramezani E, Dehghani S, Shirkoohi NM, et al
   Relationship between diet quality and inflammatory bowel disease: a systematic review of observational studies.
   BMC Gastroenterol. 2025;25:756.
   PubMed         Abstract available
   
   

   
   Clin Res Hepatol Gastroenterol

8. AMIOT A, Kirchgesner J, Alric H, Treton X, et al
   Five-year effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
   Clin Res Hepatol Gastroenterol. 2025 Dec 5:102741.
   PubMed         Abstract available
   
   

   
   Dig Dis

9. SARBAGILI-SHABAT C, Zelber-Sagi S, Fliss Isakov N, Hirsch A, et al
   Physical activity is inversely associated with clinical exacerbation in patients with Crohn's disease in remission - a prospective cohort study.
   Dig Dis. 2025 Dec 11:1-14. doi: 10.1159/000550048.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

10. GADE A, Saraga A, Deyhim T, Geeganage G, et al
    Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated with Less Treatment Failure in Patients with Inflammatory Bowel Disease Treated with Adalimumab.
    Dig Dis Sci. 2025 Dec 9. doi: 10.1007/s10620-025-09597.
    PubMed         Abstract available
    
    
11. DESAI A, Kochhar GS, Khataniar H, Hashash JG, et al
    Risk of Incident Immune-Mediated Inflammatory Diseases with Second Tumor Necrosis Factor Inhibitor Versus Alternative Biologic Therapy in Patients with Inflammatory Bowel Disease and First TNFi Exposure: A Real-World Cohort Study.
    Dig Dis Sci. 2025 Dec 9. doi: 10.1007/s10620-025-09598.
    PubMed         Abstract available
    
    
12. GORE E, Femino C, Aronskyy I, Miller A, et al
    Correction: The Patient Experience with Point-of-Care Intestinal Ultrasound for Inflammatory Bowel Disease Monitoring: A Multicenter Study.
    Dig Dis Sci. 2025 Dec 6. doi: 10.1007/s10620-025-09542.
    PubMed        
    
    
13. XU S, Zhang P, Li N, Liu J, et al
    IFX Is Associated with Higher Rates of 2-Year Mucosal Healing in Biologic-Naive CD Patients Compared to UST.
    Dig Dis Sci. 2025;70:4235-4246.
    PubMed         Abstract available
    
    

    
    Dis Colon Rectum

14. BAK MTJ, Pierik RB, Rizopoulos D, Stassen LPS, et al
    Cross-Cultural Translation and Validation of the Crohn's Anal Fistula Quality of Life Scale in Patients With Active Perianal Fistulizing Crohn's Disease.
    Dis Colon Rectum. 2025 Dec 10. doi: 10.1097/DCR.0000000000004051.
    PubMed         Abstract available
    
    

    
    Gastroenterology

15. THIAGARAJAH JR
    Tiptoeing in from the fatty fringes: mechanosensitive fibroblasts and Crohn's Disease.
    Gastroenterology. 2025 Dec 8:S0016-5085(25)06614.
    PubMed        
    
    

    
    Gut

16. ZHOU L, Nie J, Feng Z, Li R, et al
    Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn's disease.
    Gut. 2025 Dec 13:gutjnl-2025-336415. doi: 10.1136/gutjnl-2025-336415.
    PubMed         Abstract available
    
    
17. TURNER D, Kenigsberg S, Focht G, Turpin W, et al
    Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials.
    Gut. 2025 Dec 11:gutjnl-2025-336368. doi: 10.1136/gutjnl-2025-336368.
    PubMed         Abstract available
    
    
18. SCHREIBER S, Aden K, Tran F, Rosenstiel P, et al
    Rise of precision medicine: can it deliver on its promise in IBD?
    Gut. 2025;75:176-188.
    PubMed         Abstract available
    
    
19. MIYAUCHI E, Taida T, Uchiyama K, Nakanishi Y, et al
    Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota.
    Gut. 2025;75:46-56.
    PubMed         Abstract available
    
    
20. DE LUCA R, Arre V, Nardone S, Incerpi S, et al
    Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling.
    Gut. 2025;75:161-175.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

21. GOLDMAN A, Idan L, Ben-Horin S, Kopylov U, et al
    Computer-Aided Detection Colonoscopy for Surveillance in IBD Patients: Insights from a Single-Center Experience.
    Inflamm Bowel Dis. 2025;31:3379-3384.
    PubMed         Abstract available
    
    
22. BERTANI L, Ribaldone DG, Bossa F, Guerra M, et al
    When to Switch to Subcutaneous Infliximab? The RE-WATCH Multicenter Study.
    Inflamm Bowel Dis. 2025;31:3363-3369.
    PubMed         Abstract available
    
    
23. FIRMBACH D, Lang-Schwarz C, Rubio CA, Hartmann A, et al
    Quantitative Analysis of Distinct Colon Crypt Branching Modes Using Interpretable Machine Learning.
    Inflamm Bowel Dis. 2025;31:3407-3416.
    PubMed         Abstract available
    
    
24. BERLIN P, Fischer A, Bergmann-Ewert W, Kordt M, et al
    Perioperative anti-alpha4beta7 Integrin Blockade Alters Wound Cell Infiltrate but Not the Functional Outcome of Ileocecal Anastomoses in Mice With Crohn's-like Ileitis.
    Inflamm Bowel Dis. 2025;31:3385-3397.
    PubMed         Abstract available
    
    
25. HOU G, Lee A, Golob JL, Grasberger H, et al
    IL-15 Promotes Inflammatory Th17 Cells in the Intestine.
    Inflamm Bowel Dis. 2025;31:3417-3428.
    PubMed         Abstract available
    
    
26. BERTANI L, Ribaldone DG, Bossa F, Guerra M, et al
    Reply: "Early Switching to Subcutaneous Infliximab as a Pragmatic Strategy for Optimized Inflammatory Bowel Disease Care".
    Inflamm Bowel Dis. 2025 Dec 5:izaf264. doi: 10.1093.
    PubMed        
    
    
27. NISHIDA Y, Hosomi S, Fujimoto K, Kobayashi Y, et al
    Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis.
    Inflamm Bowel Dis. 2025 Dec 8:izaf302. doi: 10.1093.
    PubMed         Abstract available
    
    
28. RAISANEN L, Lang R, Couper M, Lewindon P, et al
    Bowel Wall Thickness Cutoff Value for Assessing Inflammatory Bowel Disease Activity Using Intestinal Ultrasonography in Children.
    Inflamm Bowel Dis. 2025 Dec 8:izaf298. doi: 10.1093.
    PubMed         Abstract available
    
    
29. KAIEDA Y, Sugimoto S, Suzuki T, Matsumoto S, et al
    Characterization of Computed Tomography Colonography Findings of Ulcerative Colitis-Associated Neoplasia.
    Inflamm Bowel Dis. 2025 Dec 9:izaf303. doi: 10.1093.
    PubMed         Abstract available
    
    
30. DESAI A, Habib H, Khataniar H, Farraye FA, et al
    Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients With Ulcerative Colitis and IPAA With a History of Pouchitis.
    Inflamm Bowel Dis. 2025 Dec 9:izaf301. doi: 10.1093.
    PubMed         Abstract available
    
    
31. SYED S, Moayyedi P, Kao D, Patel J, et al
    Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Remission in Ulcerative Colitis: An Open-Label Pilot Study.
    Inflamm Bowel Dis. 2025 Dec 10:izaf284. doi: 10.1093.
    PubMed        
    
    
32. MARCHESE SH, Raza HS, Naffouj S, Mutlu E, et al
    Black and Latino/a Participants With Inflammatory Bowel Disease Are More Likely to Be at Risk for Post-Traumatic Stress Than Their White Counterparts: A Matched Control Comparison Study.
    Inflamm Bowel Dis. 2025 Dec 10:izaf290. doi: 10.1093.
    PubMed         Abstract available
    
    
33. OSOOLI M, Voghera S, Bruze G, Nordenvall C, et al
    Trends in Use of Prescribed Opioids in Incident and Prevalent Patients With Ulcerative Colitis: A Nationwide Study in Sweden.
    Inflamm Bowel Dis. 2025 Dec 11:izaf278. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

34. FRIGERIO S, Khan HN, Amini M, Mol B, et al
    Spatial transcriptomics and immunophenotyping uncover chronic inflammation-induced immune adaptations favoring dysplasia development in patients at risk of colitis-associated cancer.
    J Crohns Colitis. 2025;19:jjaf184.
    PubMed         Abstract available
    
    
35. NEWMAN KL, Naftaly JP, Wren PA, Long MD, et al
    Direct and indirect impacts of discrimination, internalized stigma, and disease disclosure on inflammatory bowel disease patient health outcomes.
    J Crohns Colitis. 2025;19:jjaf192.
    PubMed         Abstract available
    
    
36. DE CRISTOFARO E, Marafini I, Franchin M, Venuto C, et al
    Frequency of dysplasia in endoscopically resected pseudopolyps in inflammatory bowel diseases.
    J Crohns Colitis. 2025;19:jjaf196.
    PubMed         Abstract available
    
    
37. PEYRIN-BIROULET L, Atreya R, Danese S, Lindsay JO, et al
    Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study.
    J Crohns Colitis. 2025 Dec 4:jjaf213. doi: 10.1093.
    PubMed         Abstract available
    
    
38. WASHBURN S, Hwang Y, Chowdary Maddipatla S, Murthy S, et al
    Identification of Crohn's disease subtypes in single cell RNA sequencing signatures of treatment naive samples across the paediatric gastrointestinal tract.
    J Crohns Colitis. 2025 Dec 10:jjaf225. doi: 10.1093.
    PubMed         Abstract available
    
    
39. ZHANG Q, Sharip M, Roberts C, Shakweh E, et al
    HLA-DQA1*05:01 and DQA1*05:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease.
    J Crohns Colitis. 2025;19:jjaf195.
    PubMed         Abstract available
    
    

    
    PLoS One

40. ASLAM MN, Turgeon DK, Appelman HD, Stidham R, et al
    A multi-mineral intervention to improve disease-related and mechanistic biomarkers in ulcerative colitis patients: Results from a randomized trial.
    PLoS One. 2025;20:e0337408.
    PubMed         Abstract available
    
    
41. VASQUEZ JN, Doncel P, Camacho J, Ruiz E, et al
    Targeted virome deep sequencing reveals frequent herpesvirus detection in intestinal biopsies of inflammatory bowel disease patients.
    PLoS One. 2025;20:e0337322.
    PubMed         Abstract available
    
    
42. LI R, Sun Y, Kelsang D, Feng M, et al
    Butyrate ameliorates DSS-induced ulcerative colitis in mice by facilitating autophagy in intestinal epithelial cells and modulating the gut microbiota through blocking the PI3K-AKT-mTOR pathway.
    PLoS One. 2025;20:e0337214.
    PubMed         Abstract available
    
    

    
    Scand J Gastroenterol

43. SUBIC Z, Drobne D, Novak G
    High persistence and efficacy of ustekinumab as a first-line biological therapy in inflammatory bowel disease: a real-world cohort study.
    Scand J Gastroenterol. 2025 Dec 8:1-9. doi: 10.1080/00365521.2025.2597263.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.